Ritter Pharmaceuticals | Therapeutic Treatments for Gastrointestinal Diseases

LOS ANGELES (November 2, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the Company’s Chief Executive Officer, Michael Step, will present at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic Congress on November 3, 2017, in San Diego. Mr. Step presentation is entitled: “Pioneering Development in the Gut Microbiome for the Treatment of Lactose Intolerance.”

About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. (www.RitterPharma.com, @RitterPharma) develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP‐G28, has the potential to become the first FDA‐approved treatment for lactose intolerance, a condition that affects millions worldwide. The Company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno‐oncology, metabolic, and liver disease.

Forward‐Looking Statements
This release may contain forward‐looking statements, which express the current beliefs and expectations of Ritter Pharmaceuticals’ management. Such statements involve a number of known and unknown risks and uncertainties that could cause the Company’s future results,  erformance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward‐looking statements. Any statements contained herein that do not describe historical facts are forward‐looking statements that involve risks and  ncertainties that could cause actual results to differ materially from those discussed in such forward‐looking statements. These forward‐looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward‐looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investor Contact:
Jeffrey Benjamin
310‐203‐1000
jeffrey@ritterpharma.com